Millions of people who bought DNA tests from genetic testing service 23andme have been urged to delete their personal data ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

DNA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire ...

23andMe is in trouble. Once a hot Silicon Valley startup, the genetic testing company has been in free fall since a major ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

GSK turned the mobile phone into a disease detection and risk evaluation tool to raise awareness of under-diagnosed and under-treated chronic obstructive pulmonary disease in China. GSK has always ...

"My life was hell": Man awarded £160,000 damages after Parkinson's drug turned him into gay sex and gambling addict ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

This report presents key facts and figures about the British pharmaceutical company GSK, formerly known as GlaxoSmithKline. GSK is one of the world's 10 largest pharmaceutical companies.

--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene ...